Histopathologic changes associated with fialuridine hepatotoxicity

Modern Pathology

Volumn 10, Issue 3, 1997, Pages 192-199

  Kleiner, David E ^a   Gaffey, Michael J ^d   Sallie, Richard ^b   Tsokos, Maria ^a   Nichols, Larry ^e   McKenzie, Robin ^c   Straus, Stephen E ^c   Hoofnagle, Jay H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hepatitis B; Drug toxicity; Fialuridine; Hepatic failure; Lactic acidosis; Microvesicular steatosis; Nucleoside analogue

Indexed keywords

FIALURIDINE;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; FEMALE; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN TISSUE; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TOXICITY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ULTRASTRUCTURE; VIRUS HEPATITIS;

ADULT; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CHRONIC DISEASE; CLINICAL TRIALS, PHASE II; FEMALE; HEPATITIS B; HEPATITIS, TOXIC; HUMANS; LIVER; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 0030997076     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Dusheiko G, Hoofnagle JH. Hepatitis B. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, editors. Oxford textbook of clinical hepatology. New York: Oxford University Press, 1991;571-92.
2. Craig JR, Peters RL, Edmondson HA. Tumors of the liver and intrahepatic bile ducts. In: Hartmann WH, Sobin LH, editors. Atlas of tumor pathology. Vol. 26. Washington, DC: Armed Forces Institute of Pathology 1989.
3. Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol 1995;22 Suppl 1:65-7.
4. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
5. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Annu Intern Med 1993;119:312-23.
6. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
7. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
8. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients [letter]. Lancet 1995;345:396-7.
9. Kruger M, Tillman HL, Trautwein C, Oldhafer K, Baker KHW, Pichlmayr R, et al. Famiciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation: a pilot study [abstract]. Hepatology 1995;22:219A.
10. Fourel I, Li J, Hantz O, Jacquet C, Fox JJ, Trepo C. Effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J Med Virol 1992;37:122-6.
11. Fried MW, Di Bisceglie AM, Straus SE, Savarese B, Bemes MP, Hoofnagle JH. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B [abstract]. Hepatology 1992;16:127A.
12. Paar DP, Hooten TH, Smiles KA, Di Bisceglie AM, Havlir DV, Richman DD, et al. The effect of FIAU on chronic hepatitis B virus (HBV) infection in HIV-infected subjects (ACTG 122b) [abstract]. In: Program and Abstracts of the 32nd Interscience Conference on Anti-Microbial Agents and Chemotherapy; 1992 Oct 11-14; Anaheim (CA):264.
13. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
14. Stevenson W, Gaffey M, Ishitani M, McCullough C, Dickson R, Caldwell S, et al. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Transplant Proc 1995;27: 1219-21.
15. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
16. Bove KE, McAdams AJ, Partin JC, Partin JS, Hug G, Schubert WK. The hepatic lesion in Reye's syndrome. Gastroenterology 1975;69:685-97.
17. Peters LJ, Wiener GJ, Gilliam J, van Noord G, Geisinger KR, Roach ES. Reye's syndrome in adults. A case report and review of the literature. Arch Intern Med 1986;146:2401-3.
18. Uchida T, Kao H, Quispe-Sjogren M, Peters RL. Alcoholic foamy degeneration: a pattern of acute alcoholic injury of the liver. Gastroenterology 1983;84:683-92.
19. Rolfes DB, Ishak KG. Liver disease in pregnancy. Histopathology 1986;10:555-70.
20. Hill KR. The vomiting sickness of Jamaica: a review. West Indian Med J 1952;1:243-64.
21. Billington D, Osmundsen H, Sherratt HS. The biochemical basis of Jamaican akee poisoning. N Engl J Med 1976;1482.
22. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 1982;2:591-7.
23. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984;25:673-81.
24. Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline toxicity. Am J Med 1965;38:359-77.
25. Chang CH, Uchwat F, Masalskis F, Arcinue EL. Morphologic grading of hepatic mitochondrial alteration in Reye's syndrome: potential prognostic implication. Pediatr Pathol 1985;4:265-75.
26. Daugherty CC, Gartside PS, Heubi JE, Saalfeld K, Snyder J. A morphometric study of Reye's syndrome. Correlation of reduced mitochondrial numbers and increased mitochondrial size with clinical manifestations. Am J Pathol 1987;129:313-26.
27. Partin J, Schubert W, Partin J. Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera). N Engl J Med 1971;285:1339-43.
28. Gopinath R, Hutcheon M, Cheema-Dhadli S, Halperin M. Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: biochemical studies. J Am Soc Nephrol 1992;3:1212-9.
29. Gradon JD, Chapnick EK, Sepkowitz DV. Zidovudine-induced hepatitis. J Intern Med 1992;231:317-8.
30. Chattha G, Arieff AI, Cummings C, Tierney LMJ. Lactic acidosis complicating the acquired immunodeficiency syndrome. Annu Intern Med 1993;118:37-9.
31. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. Aids 1993;7:379-85.
32. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Annu Intern Med 1991;115:283-4.
33. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, et al. Fulminant hepatic failure with severe lactic acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994;235:367-71.
34. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffen JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098-105.
35. Lewis W, Gonzalez B, Chomyn A, Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 1992;89: 1354-60.
36. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992;87:708-13.
37. Coffin E, Horsmans Y, Pirson Y, Cornu C, Geubel A, van Ypersele De Strihou C. Acute necrotico-hemorrhagic pancreatitis after famciclovir prescription. Transplantation 1995;59: 1218-9.
38. Lau D, Mostowski H, Hoofnagle JH, Sallie R. Nucleoside analogue toxicity and mitochondria [abstract]. Hepatology 1994;20:189A.
39. Levine ES, Colacino JM, Bowsher RR, Sallie R, Lewis W. FIAU incorporates into DNA from human liver and from human hepatoblastoma cells [abstract]. Hepatology 1994;20:189A.